S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
Investing Wizard Who Turned $37K Into $2.7M in Just 4 Years Makes His Next Big Move (Ad)
Stock market today: Wall Street clings to modest gains and marks another winning week
Dropbox’s stock is a falling knife worth catching
Laser breakthrough could send stock soaring 2,467% (Ad)
Novavax’s dispute resolution and upcoming earnings call
Stock ideas from the 2024 Microcap Conference
Laser breakthrough could send stock soaring 2,467% (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Warner Bros. Discover: Debt down, profits up, yet questions remain
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
Investing Wizard Who Turned $37K Into $2.7M in Just 4 Years Makes His Next Big Move (Ad)
Stock market today: Wall Street clings to modest gains and marks another winning week
Dropbox’s stock is a falling knife worth catching
Laser breakthrough could send stock soaring 2,467% (Ad)
Novavax’s dispute resolution and upcoming earnings call
Stock ideas from the 2024 Microcap Conference
Laser breakthrough could send stock soaring 2,467% (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Warner Bros. Discover: Debt down, profits up, yet questions remain
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
Investing Wizard Who Turned $37K Into $2.7M in Just 4 Years Makes His Next Big Move (Ad)
Stock market today: Wall Street clings to modest gains and marks another winning week
Dropbox’s stock is a falling knife worth catching
Laser breakthrough could send stock soaring 2,467% (Ad)
Novavax’s dispute resolution and upcoming earnings call
Stock ideas from the 2024 Microcap Conference
Laser breakthrough could send stock soaring 2,467% (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Warner Bros. Discover: Debt down, profits up, yet questions remain
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
Investing Wizard Who Turned $37K Into $2.7M in Just 4 Years Makes His Next Big Move (Ad)
Stock market today: Wall Street clings to modest gains and marks another winning week
Dropbox’s stock is a falling knife worth catching
Laser breakthrough could send stock soaring 2,467% (Ad)
Novavax’s dispute resolution and upcoming earnings call
Stock ideas from the 2024 Microcap Conference
Laser breakthrough could send stock soaring 2,467% (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Warner Bros. Discover: Debt down, profits up, yet questions remain

Ensysce Biosciences (ENSC) Competitors

$0.88
-0.02 (-2.22%)
(As of 02/23/2024 ET)

ENSC vs. SLRX, ALLR, CNSP, CING, NMTR, ZVSA, MNPR, KLDO, ORGS, and ADXN

Should you be buying Ensysce Biosciences stock or one of its competitors? The main competitors of Ensysce Biosciences include Salarius Pharmaceuticals (SLRX), Allarity Therapeutics (ALLR), CNS Pharmaceuticals (CNSP), Cingulate (CING), 9 Meters Biopharma (NMTR), ZyVersa Therapeutics (ZVSA), Monopar Therapeutics (MNPR), Kaleido Biosciences (KLDO), Orgenesis (ORGS), and Addex Therapeutics (ADXN). These companies are all part of the "medical" sector.

Ensysce Biosciences vs.

Salarius Pharmaceuticals (NASDAQ:SLRX) and Ensysce Biosciences (NASDAQ:ENSC) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, dividends, valuation, profitability, institutional ownership, media sentiment, earnings, risk and analyst recommendations.

Salarius Pharmaceuticals has a beta of 0.99, indicating that its share price is 1% less volatile than the S&P 500. Comparatively, Ensysce Biosciences has a beta of 0.88, indicating that its share price is 12% less volatile than the S&P 500.

Salarius Pharmaceuticals has a net margin of 0.00% compared to Salarius Pharmaceuticals' net margin of -401.40%. Ensysce Biosciences' return on equity of -236.94% beat Salarius Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Salarius PharmaceuticalsN/A -236.94% -159.70%
Ensysce Biosciences -401.40%-6,580.48%-261.01%

5.9% of Salarius Pharmaceuticals shares are held by institutional investors. Comparatively, 31.0% of Ensysce Biosciences shares are held by institutional investors. 5.5% of Salarius Pharmaceuticals shares are held by company insiders. Comparatively, 52.7% of Ensysce Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Salarius Pharmaceuticals received 23 more outperform votes than Ensysce Biosciences when rated by MarketBeat users. However, 60.00% of users gave Ensysce Biosciences an outperform vote while only 54.17% of users gave Salarius Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
Salarius PharmaceuticalsOutperform Votes
26
54.17%
Underperform Votes
22
45.83%
Ensysce BiosciencesOutperform Votes
3
60.00%
Underperform Votes
2
40.00%

Ensysce Biosciences has higher revenue and earnings than Salarius Pharmaceuticals. Salarius Pharmaceuticals is trading at a lower price-to-earnings ratio than Ensysce Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Salarius Pharmaceuticals$1.84M1.24-$31.61M-$7.14-0.08
Ensysce Biosciences$2.52M1.10-$24.17M-$22.18-0.04

In the previous week, Salarius Pharmaceuticals had 1 more articles in the media than Ensysce Biosciences. MarketBeat recorded 3 mentions for Salarius Pharmaceuticals and 2 mentions for Ensysce Biosciences. Salarius Pharmaceuticals' average media sentiment score of 0.27 beat Ensysce Biosciences' score of 0.12 indicating that Ensysce Biosciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Salarius Pharmaceuticals
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Ensysce Biosciences
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Ensysce Biosciences has a consensus price target of $11.00, indicating a potential upside of 1,150.28%. Given Salarius Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Ensysce Biosciences is more favorable than Salarius Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Salarius Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Ensysce Biosciences
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Ensysce Biosciences beats Salarius Pharmaceuticals on 10 of the 18 factors compared between the two stocks.


Get Ensysce Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for ENSC and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENSC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ENSC vs. The Competition

MetricEnsysce BiosciencesPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$2.77M$6.75B$5.04B$7.52B
Dividend YieldN/A2.79%2.87%3.86%
P/E Ratio-0.0418.39248.2218.81
Price / Sales1.10144.603,012.0155.11
Price / CashN/A18.2289.6452.42
Price / Book-0.124.584.364.64
Net Income-$24.17M$158.86M$112.68M$207.29M
7 Day Performance-5.31%1.04%0.91%-1.14%
1 Month Performance-33.85%10.97%7.22%3.54%
1 Year Performance-85.71%4.16%10.46%5.53%

Ensysce Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SLRX
Salarius Pharmaceuticals
0.2895 of 5 stars
$0.52
-7.2%
N/A-74.4%$2.04M$1.84M-0.0712News Coverage
Gap Up
ALLR
Allarity Therapeutics
0 of 5 stars
$0.41
-2.4%
N/A-99.9%$1.95MN/A0.0014News Coverage
CNSP
CNS Pharmaceuticals
0 of 5 stars
$0.28
-6.6%
N/A-83.1%$1.76MN/A0.003Positive News
Gap Down
CING
Cingulate
2.2625 of 5 stars
$1.17
+4.5%
$8.00
+583.8%
-95.3%$1.10MN/A-0.0415News Coverage
Gap Up
NMTR
9 Meters Biopharma
0 of 5 stars
N/A$1.70
+∞
N/A$1.04MN/A-0.0210
ZVSA
ZyVersa Therapeutics
2.5845 of 5 stars
$0.56
-6.7%
$87.50
+15,665.8%
-99.0%$688,000.00N/A0.007News Coverage
MNPR
Monopar Therapeutics
2.6107 of 5 stars
$0.33
flat
$13.00
+3,838.2%
-60.5%$4.91MN/A-0.4611News Coverage
Gap Up
KLDO
Kaleido Biosciences
0 of 5 stars
N/AN/AN/A$6.39M$1.10M0.0076
ORGS
Orgenesis
3.9783 of 5 stars
$0.30
flat
$6.00
+1,927.0%
-57.9%$9.44M$36.03M-0.33167News Coverage
ADXN
Addex Therapeutics
0 of 5 stars
$10.42
+0.7%
N/A-77.4%$10.32M$1.51M-0.5424News Coverage
Positive News
Gap Down

Related Companies and Tools

This page (NASDAQ:ENSC) was last updated on 2/24/2024 by MarketBeat.com Staff